washington u.s. congressional panel ask pharmaceutical entrepreneur martin shkreli testify jan. 26 hear company decision raise price life-saving prescription drug accord republican committee staffer shkreli become know pharma bro create fire storm last year company turing pharmaceuticals hike price drug call daraprim 5,000 percent last month shkreli force step turing ceo amid criminal civil securities fraud charge allege run ponzi-like scheme tenure hedge fund msmb capital management ceo retrophin another drug company previously head securities fraud charge unrelated drug price probe committee hear house representatives committee oversight government reform primarily focus turing price spike daraprim price hike two valeant pharmaceutical heart medications isuprel nitropress democratic committee staffer tell reuters friday valeant interim ceo howard schiller also expect appear hear valeant spokeswoman confirm schiller attend say look forward testify company cooperate ongoing congressional probe attorney shkreli decline comment early month house oversight chairman jason chaffetz rank member elijah cummings jointly send document request valeant turing shkreli request lawmakers ask document show company gross revenues profit sales drug question well communications ceos connection drug since turing give tens thousands document u.s. congressional investigators ahead hear accord democratic committee staffer spokeswoman turing immediate comment committee expect review another batch document valeant near future deadline submission jan. 22. house oversight panel interest drug price spark cummings year call republican-led panel probe prescription drug price statement cummings say glad bipartisan support investigation say americans feed watch major drug company rake record profit continue struggle afford medicine house committee seek testimony 'pharma bro shkreli